Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Cash from Financing Activities (2016 - 2025)

China Pharma Holdings filings provide 15 years of Cash from Financing Activities readings, the most recent being -$72592.0 for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 33.61% to -$72592.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$294027.0, a 770.37% decrease, with the full-year FY2025 number at -$294027.0, down 770.37% from a year prior.
  • Cash from Financing Activities hit -$72592.0 in Q4 2025 for China Pharma Holdings, up from -$122214.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $4.6 million in Q4 2021 to a low of -$850555.0 in Q2 2022.
  • Median Cash from Financing Activities over the past 5 years was -$41760.5 (2024), compared with a mean of $128653.4.
  • Biggest five-year swings in Cash from Financing Activities: soared 45928.53% in 2021 and later crashed 1885.97% in 2025.
  • China Pharma Holdings' Cash from Financing Activities stood at $4.6 million in 2021, then tumbled by 114.55% to -$672063.0 in 2022, then soared by 104.52% to $30378.0 in 2023, then plummeted by 278.86% to -$54333.0 in 2024, then crashed by 33.61% to -$72592.0 in 2025.
  • The last three reported values for Cash from Financing Activities were -$72592.0 (Q4 2025), -$122214.0 (Q3 2025), and -$29188.0 (Q2 2025) per Business Quant data.